New drug duo tested to fight back against Tough-to-Treat cancers
NCT ID NCT04802174
Summary
This study is testing whether combining two drugs, lurbinectedin and berzosertib, can shrink tumors in people with aggressive small cell lung cancer or high-grade neuroendocrine cancers that have returned after prior treatment. The first part of the trial aims to find the safest dose, and the second part will see how well the combination works. Adults with these cancers who have progressed on standard therapies may be eligible to participate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.